



May 10, 2022

## **Notice on the Formulation of a Share Buyback Policy**

Santen Pharmaceutical Co., Ltd. (Head Office: Osaka; President and CEO: Shigeo Taniuchi; hereinafter, “Santen” or the “Company”) announced today its formulation of a share buyback policy

### Share Buyback policy

Santen regards returning profits to shareholders as a top management priority. Our basic allocation policy consists of a proactive capital deployment to strategic investments and shareholders that contribute to our enterprise value.

The medium-term plan, MTP2025, announced on May 19, 2021, included a policy consisting of a dividend payout ratio of at least 40% and share buybacks to be conducted flexibly up to FY2025.

Based on a comprehensive consideration and assessment of factors such as the state of the Company’s share price, earnings outlook, and financial conditions, we have deemed appropriate to set the Company’s total payout ratio, including dividends and share buybacks, to approximately 150% as part of our FY2022 shareholder return policy.

This Notice consists of the Formulation of a policy. Specific share buybacks shall be separately resolved by Santen’s Board of Directors under Article 156 of the Companies Act (Japan), as applied pursuant to Article 165, paragraph 3, subject to several factors including but not limited to equity market conditions, and the Company’s financial conditions, and disclosed accordingly.

### **Contact:**

Guillaume Sakuma  
Global Head of IR, IR Group  
E-mail: [ir@santen.com](mailto:ir@santen.com)

### **About Santen**

As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices, and its products now reach patients in over 60 countries.

Toward realizing “WORLD VISION” (Happiness with Vision), the world Santen ultimately aspires to achieve, as a “Social Innovator”, we aim to reduce the social and economic opportunity loss of people around the world caused by eye diseases and defects by orchestrating and mobilizing key technologies and players around the world.

With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society.

For more information, please visit Santen’s website (<https://www.santen.com/en/>).